Clinical Trials | September 03, 2024
Tolebrutinib meets primary endpoint in HERCULES phase 3 study
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Phase 3 study results will form the basis for future discussions with global regulatory authorities
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Subscribe To Our Newsletter & Stay Updated
